NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $68.43 -2.19 (-3.10%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$68.40 -0.03 (-0.04%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nektar Therapeutics Stock (NASDAQ:NKTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$66.31▼$71.0050-Day Range$65.25▼$100.3552-Week Range$7.99▼$109.00Volume1.23 million shsAverage Volume1.35 million shsMarket Capitalization$2.31 billionP/E RatioN/ADividend YieldN/APrice Target$149.63Consensus RatingModerate Buy Company Overview Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases. Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs. Notable examples are NKTR-214 (bempegaldesleukin), an immuno-oncology agent designed to stimulate T-cell and natural killer cell activity in combination with checkpoint inhibitors, and NKTR-255, an IL-15 receptor agonist intended to enhance immune responses in oncology and infectious diseases. The company’s earlier polymer conjugate derivative of irinotecan, etirinotecan pegol, was licensed to a global partner for the treatment of metastatic breast cancer, underscoring Nektar’s expertise in drug delivery innovation. Founded in 1990 and headquartered in San Francisco, Nektar operates research and development facilities in the United States and collaborates with international pharmaceutical companies to advance its pipeline. Its partnerships have included agreements with Bristol-Myers Squibb and AstraZeneca, reflecting a strategy of combining its novel molecules with established therapies to maximize patient benefit. Under the leadership of President and Chief Executive Officer Howard W. Robin, Nektar continues to invest in its core technology platforms. The management team brings deep experience in biopharmaceutical development, clinical operations and global regulatory affairs, positioning the company to progress multiple candidates through clinical trials and toward potential regulatory approval.AI Generated. May Contain Errors. Read More Nektar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreNKTR MarketRank™: Nektar Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 391st out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNektar Therapeutics has a consensus price target of $149.63, representing about 118.7% upside from its current price of $68.43.Amount of Analyst CoverageNektar Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nektar Therapeutics are expected to decrease in the coming year, from ($9.65) to ($11.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 15.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.47% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 2.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 12.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.69 News SentimentNektar Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Nektar Therapeutics this week, compared to 12 articles on an average week.Search Interest15 people have searched for NKTR on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTR Stock News HeadlinesNektar Therapeutics (NASDAQ:NKTR) Raised to "Hold" at Wall Street ZenMay 17 at 1:14 AM | americanbankingnews.comPatient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 SharesMay 16 at 1:01 PM | fool.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 19 at 1:00 AM | Weiss Ratings (Ad)Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price MomentumMay 14, 2026 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Price Target Lowered to $80.00 at WedbushMay 12, 2026 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Expected to Rise, Piper Sandler Analyst SaysMay 10, 2026 | americanbankingnews.comNektar Therapeutics Establishes New Equity Distribution AgreementMay 10, 2026 | theglobeandmail.comNektar Therapeutics Charts Aggressive Path With REZPEGMay 8, 2026 | tipranks.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $42.28 at the start of the year. Since then, NKTR shares have increased by 61.8% and is now trading at $68.43. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.58) by $0.24. The biopharmaceutical company earned $10.86 million during the quarter, compared to analyst estimates of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative trailing twelve-month return on equity of 85.40%. Read the conference call transcript. When did Nektar Therapeutics' stock split? Nektar Therapeutics's stock reverse split on the morning of Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' top institutional shareholders include Emerald Advisers LLC (1.17%), Orbimed Advisors LLC (0.81%), Emerald Mutual Fund Advisers Trust (0.76%) and ADAR1 Capital Management LLC (0.48%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Jonathan Zalevsky, Robert Chess, Roy A Whitfield and Myriam Curet. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol Myers Squibb (BMY), Netflix (NFLX) and ExxonMobil (XOM). Company Calendar Last Earnings5/07/2026Today5/19/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NKTR's financial health is in the Green zone, according to TradeSmith. NKTR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees220Year Founded1990Price Target and Rating Average Price Target for Nektar Therapeutics$149.63 High Price Target$192.00 Low Price Target$80.00 Potential Upside/Downside+118.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($8.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.08 million Net Margins-284.18% Pretax Margin-273.59% Return on Equity-85.40% Return on Assets-39.99% Debt Debt-to-Equity RatioN/A Current Ratio10.21 Quick Ratio10.21 Sales & Book Value Annual Sales$55.23 million Price / Sales41.87 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book15.52Miscellaneous Outstanding Shares33,790,000Free Float32,941,000Market Cap$2.31 billion OptionableOptionable Beta1.24 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NKTR) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
